NeuroSoV is dedicated to the development of therapies targeted at slowing down the Parkinson Disease (PD), which is a devastating pandemics, accounting for a total annual economic burden of ~$52billions in USA and ~€12,5 billions in Europe.
We are developing a new drug candidate for PD. Our company have reformulated a specific molecule capable of reducing PD progression. It’s our goal to license the molecule to the pharma industry once the pre-clinical validation is completed.
NeuroSoV has other molecules in its pipeline that are analogs for this molecule and we are developing.
But NeuroSoV is also about providing a set of lab services for pharmaceutical industries and research laboratories. NeuroSoV Services comprises: use of state of the art models to perform pré-clinical validation of molecules with therapeutic potential for Parkinson’s disease.
NeuroSoV is a pre-clinical Contract Research Organization (CRO), dedicated to evaluating the therapeutic efficacy of new molecules for Parkinson’s disease.
We aim to accelerate your project outputs helping you to validate your hypothesis or molecules using a vast set of experimental models of Parkinson’s disease.
We will propose you the best models and tests for your project. With NeuroSoV, you will reduce the chances of clinical trial fails.